| Detected | Trial | Change |
|---|---|---|
| 2026-05-21 | NCT06038526 Evaluation of Canakinumab in High-Risk Former-Smokers |
date change Primary completion pushed: 2026-04-30 -> 2026-07-30 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT05535738 | Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation | Skin Inflammation | Active, Not Recruiting |
| Phase 2 | |||
| NCT05641831 | Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal… | Clonal Cytopenia of Undetermined Significance | Recruiting |
| NCT04789681 | Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial | Lung Carcinoma | Recruiting |
| NCT06691217 | Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis | Vascular Inflammation | Recruiting |
| NCT04239157 | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal… | Chronic Myelomonocytic Leukemia | Recruiting |
| NCT05467800 | Study of Canakinumab in Patients With Myelofibrosis | Primary Myelofibrosis | Active, Not Recruiting |
| NCT06038526 | Evaluation of Canakinumab in High-Risk Former-Smokers | Cigarette Smoking-Related Carcinoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT05984602 | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab… | Pancreatic Cancer | Active, Not Recruiting |
| Not specified | |||
| NCT06838143 | Ilaris NIS in Korea | Hereditary Periodic Fever Syndromes | Recruiting |